Conference call scheduled for 4:30 p.m. ET today
- VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2
Meeting Planned for 2H24
- Oral VK2735 Phase 2 Study in Obesity Expected to Begin
4Q24
- Positive Biopsy Results From VK2809 Reported in June;
End-of-Phase 2 Meeting in NASH/MASH Planned for 4Q24
- Enrollment Completed in Phase 1b Study of VK0214 for X-ALD; Data Expected
2H24
- In Vivo Data From Novel Amylin Agonist Program Reported at
ADA in June; IND in Obesity Planned for 2025
SAN
DIEGO, July 24, 2024 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, today announced
its financial results for the second quarter and six months ended
June 30, 2024, and provided an update
on its clinical pipeline and other corporate developments.
Highlights from the Quarter Ended June
30, 2024, and Other Recent Events:
"The first half of 2024 was marked by strong momentum in the
company's pipeline programs, as we reported successful outcomes
from three different clinical trials, and began preparing for next
steps with each program," stated Brian
Lian, Ph.D., chief executive officer of Viking. "The
Phase 2 VENTURE study of VK2735 in obesity demonstrated up to an
approximately 15% reduction in body weight from baseline following
13 weeks of dosing, as well as promising safety and tolerability.
Following receipt of written feedback from an FDA Type C
meeting, we are advancing this compound into Phase 3
development. We are currently preparing for an end of Phase 2
meeting with the agency, which we expect to occur later this
year. Separately, the Phase 1 study of the oral tablet
formulation of VK2735 demonstrated encouraging safety and
tolerability, and positive signs of clinical activity, with
subjects reporting mean weight loss of up to 5.3% from baseline
following 28 days of daily oral dosing. Dose escalation
continues, and we expect to initiate a Phase 2 trial for this
program later this year.
"We also recently reported best-in-class histology data from the
Phase 2b VOYAGE study of our thyroid
hormone beta receptor agonist VK2809 in biopsy-confirmed NASH and
fibrosis, and plan to schedule an end of Phase 2 meeting with the
FDA later this year. With our earlier-stage programs, we are
happy to report that the Phase 1b
study of our second thyroid hormone beta receptor agonist VK0214,
for X-linked adrenoleukodystrophy, is fully enrolled and we expect
to report the results from this trial later this year.
Finally, at the ADA conference in June, we reported promising in
vivo data from a novel series of internally developed amylin
agonists and expect to file an IND for this program in 2025.
To support Viking's maturing pipeline, the company ended the
quarter with a strong balance sheet of $942
million, providing the runway to execute key milestones for
each of our pipeline programs."
Pipeline and Recent Corporate Highlights
- Reported Positive Clinical Results from Phase 2 VENTURE
Study of Subcutaneous VK2735 for Obesity in 1H24; To Advance into
Phase 3 Development. VK2735 is a wholly owned dual agonist
of the glucagon like peptide-1, or GLP-1 receptor, and the glucose
dependent insulinotropic polypeptide, or GIP receptor, for the
potential treatment of obesity and other metabolic disorders.
During the first quarter of 2024, Viking announced positive
top-line results from a Phase 2 study called VENTURE. This study
was a randomized, double-blind, placebo-controlled multicenter
study designed to evaluate the safety, tolerability,
pharmacokinetics, and weight loss efficacy of VK2735, administered
subcutaneously, once weekly, for 13 weeks. The trial was designed
to enroll adults who are obese (BMI ≥30 kg/m2) or adults
who are overweight (BMI ≥27 kg/m2) with at least one
weight-related comorbid condition. The VENTURE trial
successfully achieved its primary endpoint and all secondary
endpoints, with patients receiving VK2735 demonstrating
statistically significant reductions in body weight compared with
placebo. Additionally, the study showed VK2735 to be safe and
well tolerated, with the majority of treatment emergent adverse
events (TEAEs) being categorized as mild or moderate.
With respect to the primary endpoint, patients receiving VK2735
demonstrated statistically significant reductions in mean body
weight from baseline, ranging up to 14.7%, as well as statistically
significant reductions in mean body weight relative to placebo,
ranging up to 13.1%. Statistically significant differences compared
to placebo were observed for all doses starting at Week 1 and were
maintained throughout the course of the study. Weight loss in all
treated cohorts appeared to be progressive through 13 weeks and did
not show evidence of plateauing. The company believes further
weight loss could be achieved through extended dosing beyond the
13-week treatment period of this study.
VK2735 also demonstrated encouraging safety and tolerability in the
VENTURE study, with the majority of observed adverse events (AEs)
being reported as mild or moderate. Treatment and study
discontinuation rates among VK2735 cohorts were well-balanced
compared with placebo. Of gastrointestinal (GI) related AEs, 95%
were reported as mild or moderate. Across all cohorts in the
VENTURE study, GI-related AEs were most prevalent during the first
week of the study, with observed rates generally declining through
the remainder of the study.
During the second quarter, Viking received written responses to a
U.S. Food and Drug Administration (FDA) Type C meeting packet,
submitted to the agency earlier in the quarter. Based on
agency feedback, the company plans to advance VK2735 into a Phase 3
program for obesity. Viking expects to schedule an
end-of-Phase 2 meeting with the FDA later this year. Details
on Phase 3 trial design and timing will be disclosed following the
end-of-Phase 2 meeting.
- Reported Positive Clinical Results from Phase 1 Study
Evaluating Oral VK2735 for Obesity in 1H24; Expect to Initiate Oral
Phase 2 Trial in 4Q24. In parallel with the development
of a sub-cutaneous formulation of VK2735, Viking is also developing
an oral tablet formulation of this compound. The company
believes a tablet formulation could represent an attractive
treatment option for patients who are hesitant to initiate
injection-based therapy, or for those seeking to maintain the
weight loss they have already achieved. A key advantage in
this regard is the potential to transition patients from the
subcutaneous formulation to an oral formulation which utilizes the
same molecule. Viking believes this may reduce the risk of
unexpected safety or tolerability challenges, and could be an
attractive option for both patients and clinicians.
During the first quarter, Viking reported the initial data from a
randomized, double-blind, placebo-controlled Phase 1 trial in
healthy adults with a minimum BMI of 30 kg/m2,
evaluating once-daily oral doses ranging from 2.5 mg to 40
mg. The primary objective of the study was to evaluate the
safety and tolerability of VK2735 administered as an oral tablet
once daily for 28 days. The secondary objective was to evaluate the
pharmacokinetics of orally administered VK2735 in healthy subjects.
Exploratory pharmacodynamic measures included assessments of
changes in body weight and other metrics.
With respect to safety and tolerability, oral VK2735 was shown to
be safe and well tolerated following once daily dosing for up to 28
days, at dose levels up to 40 mg. Among subjects receiving oral
VK2735, all TEAEs were reported as mild or moderate in severity,
with the majority, 76%, reported as mild. Similarly, all GI-related
AEs in this study were reported as mild or moderate, with the
majority, 79%, reported as mild. Mild nausea was reported in 14% of
subjects receiving VK2735. No vomiting was reported among subjects
receiving VK2735. Diarrhea was reported in 3% of VK2735 treated
subjects, compared with 20% of subjects receiving placebo. Overall,
no clinically meaningful differences were reported for GI AEs among
subjects treated with VK2735 compared with placebo.
An exploratory assessment of change in body weight showed that
subjects receiving oral VK2735 demonstrated dose dependent
reductions in body weight, ranging up to 5.3% from baseline.
Placebo-adjusted reductions in body weight reached up to 3.3% from
baseline. Body weight reductions compared with baseline and placebo
were statistically significant at the highest dose evaluated.
Weight loss in the 28-day window of this study was progressive at
the 20 mg and 40 mg dose levels, with no plateau observed.
Given the promising weight loss signal demonstrated after 28 days
of once daily, along with the excellent tolerability profile
observed thus far, further dose-escalation has been evaluated at
daily doses of up to 80 mg; dosing at 100 mg is ongoing.
Results from these cohorts will be reported later this year.
Viking believes that further benefits from oral dosing of
VK2735 might be anticipated from longer dosing periods. To
this end, the company plans to initiate a 13 week Phase 2 trial in
patients with obesity in the fourth quarter of this year.
- Reported Positive 52-Week Histologic Data from Phase
2b VOYAGE Study Evaluating VK2809 for
the Treatment of NASH and Fibrosis in 2Q24; Primary and Secondary
Endpoints Successfully Achieved for Both NASH and Fibrosis with
Excellent Safety and Tolerability. VK2809 is an orally
available, small molecule agonist of the thyroid hormone receptor
that is selective for liver tissue, as well as the beta isoform of
the receptor.
In the first quarter, Viking announced completion of the Phase
2b VOYAGE study evaluating VK2809 in
patients with biopsy-confirmed NASH and fibrosis. This study
was a randomized, double-blind, placebo-controlled, multicenter,
international trial designed to assess the efficacy, safety and
tolerability of VK2809 following 52 weeks of dosing in patients
with biopsy-confirmed NASH and fibrosis. Enrollment included
patients with at least 8% liver fat content as measured by magnetic
resonance imaging, proton density fat fraction, as well as F2 and
F3 fibrosis. The primary endpoint of the study evaluated the change
in liver fat from baseline to Week 12 in patients treated with
VK2809 compared to patients receiving placebo. Secondary and
exploratory endpoints assessed histologic changes, such as NASH
resolution and fibrosis improvement, following 52 weeks of
treatment.
In 2023, the company reported that VOYAGE had successfully achieved
its primary endpoint, with patients receiving VK2809 demonstrating
statistically significant reductions in liver fat content from
baseline to Week 12 as compared with placebo. The median
relative change from baseline in liver fat among patients treated
with VK2809 ranged from 38% to 55% after 12 weeks. In
addition, up to 85% of patients receiving VK2809 experienced at
least a 30% relative reduction in liver fat.
In the second quarter of 2024, Viking announced additional results
from the VOYAGE study, demonstrating the successful achievement of
the trial's secondary endpoints evaluating histologic changes
assessed by hepatic biopsy after 52 weeks of treatment. On
the secondary endpoint of NASH resolution without worsening of
fibrosis, VK2809-treated patients demonstrated NASH resolution
rates ranging from 63% to 75%, compared with 29% for placebo.
On the secondary endpoint evaluating the proportion of patients
demonstrating at least a one stage improvement in fibrosis with no
worsening of NASH, the proportion of VK2809-treated patients
demonstrating improvements in fibrosis ranged from 44% to 57%,
compared with 34% for placebo. On the secondary endpoint evaluating
the proportion of patients experiencing both the resolution of NASH
and at least a one-stage improvement in fibrosis, the proportion of
VK2809-treated patients achieving both measures ranged from 40% to
50%, compared with 20% for placebo.
Consistent with prior studies, patients receiving VK2809 in VOYAGE
demonstrated statistically significant improvements in plasma
lipids. Placebo-adjusted reductions in LDL-C ranged from 20%
to 25%, and reductions in triglycerides and atherogenic proteins
such as apolipoprotein B, lipoprotein (a), and apolipoprotein
C-III, were significantly improved relative to placebo. These
lipids have been correlated with cardiovascular risk, suggesting
that that treatment with VK2809 may offer a long-term
cardio-protective benefit.
VK2809 also demonstrated an encouraging safety and tolerability
profile through 52 weeks of treatment, with minimal differences
compared with the previously reported results from 12 weeks.
The majority, 94%, of treatment related adverse events among
patients receiving VK2809 were reported as mild or moderate.
Discontinuations due to adverse events were low and balanced across
placebo and treatment arms. VK2809 demonstrated excellent
gastrointestinal tolerability through 52 weeks of treatment, with
similar rates of nausea, diarrhea, stool frequency, and vomiting
among VK2809-treated patients as compared to placebo.
The company believes the Phase 2b
VOYAGE data demonstrate VK2809's best-in-class efficacy on both
NASH resolution and fibrosis improvement, along with the potential
for cardiovascular benefit through improvement in plasma
lipids. Viking plans to schedule an end of Phase 2 meeting
with the FDA in the fourth quarter of 2024.
- Enrollment Complete for Phase 1b Study of VK0214 in X-ALD: Results Expected
2H24. VK0214 is a novel, orally available thyroid hormone
receptor beta agonist that is being evaluated as a potential
treatment for X-linked adrenoleukodystrophy (X-ALD), a rare
neurogenerative disease for which there are currently no
pharmacologic treatment options.
The Phase 1b study of VK0214 is
enrolling patients with the adrenomyeloneuropathy, or AMN, form of
X-ALD, which is the most common form of the disorder. This trial is
a randomized, double-blind, placebo-controlled multi-center study
in adult male patients with AMN. The primary objectives of the
study are to evaluate the safety and tolerability of VK0214
administered orally, once daily for 28 days. The study also
includes an evaluation of the pharmacokinetics of VK0214 in AMN
patients, as well as an exploratory assessment of changes in plasma
levels of very long chain fatty acids.
Enrollment in the Phase 1b study of
VK0214 in adrenomyeloneuropathy was recently completed and the
company expects to announce results in the second half of 2024.
- Presented Positive Preclinical Data from New, Internally
Developed Dual Amylin and Calcitonin Receptor Agonist (DACRA)
Program at 84th Scientific Sessions of the American
Diabetes Association; Viking DACRAs Demonstrated Significant Weight
Loss in Animal Models. During the second quarter, Viking
presented preclinical data at the American Diabetes Association's
(ADA's) scientific sessions from an internally developed dual
amylin and calcitonin receptor agonist program. As the amylin
receptor plays an important role in food intake and metabolic
control, Viking believes it represents an attractive potential
target for therapeutic intervention in obesity.
The company's ADA presentation highlighted the effects of treatment
on body weight, food intake and metabolic profile in both healthy
rats and in diet-induced obese mice. The study demonstrated that
Viking's dual amylin and calcitonin receptor agonists reduced food
intake in lean rats in the period from 0 – 72 hours following a
single subcutaneous dosing. At 72 hours following a single
dose, Viking's compounds resulted in up to 8% body weight
reductions compared to vehicle-treated animals. In a rodent
model of diet-induced obesity, treatment with Viking's compounds
for 24 days resulted in up to 10% weight loss from baseline.
The company is encouraged by these initial findings and believes
that these results, as well as those from other preclinical
studies, support the continued development of amylin agonists for
obesity. Viking expects to file an IND for this program in
2025.
- Upcoming Investor Events. Viking management will
participate in the following upcoming investor events:
BTIG Biotechnology
Conference
Virtual
August 5 - 6
Morgan Stanley 22nd Annual Global
Healthcare Conference
New York,
NY
September 4 -
6
Second Quarter and Six Month 2024 Financial
Highlights
Second Quarter ended June 30,
2024 and 2023
Research and development expenses were $23.8 million for the three months ended
June 30, 2024, compared to
$13.9 million for the same period in
2023. The increase was primarily due to increased expenses related
to manufacturing for the company's drug candidates, clinical
studies, pre-clinical studies, salaries and benefits and
stock-based compensation.
General and administrative expenses were $10.3 million for the three months ended
June 30, 2024, compared to
$9.8 million for the same period in
2023. The increase was primarily due to increased expenses
related to stock-based compensation and services provided by
third-party consultants, partially offset by a decrease in expenses
related to legal and patent services.
For the three months ended June 30,
2024, Viking reported a net loss of $22.3 million, or $0.20 per share, compared to a net loss of
$19.2 million, or $0.19 per share, in the corresponding period in
2023. The increase in net loss for the three months ended
June 30, 2024, was primarily due to
the increase in research and development expenses and general and
administrative expenses, noted previously, partially offset by
increased interest income, compared to the same period in 2023.
Six Months Ended June 30, 2024
and 2023
Research and development expenses for the six months ended
June 30, 2024 were $47.9 million compared to $24.9 million for the same period in 2023. The
increase was primarily due to increased expenses related to
manufacturing for our drug candidates, clinical studies,
pre-clinical studies, stock-based compensation, salaries and
benefits, services provided by third-party consultants and
regulatory services.
General and administrative expenses for the six months ended
June 30, 2024 were $20.3 million compared to $19.4 million for the same period in 2023. The
increase was primarily due to increased expenses related to
stock-based compensation, salaries and benefits and services
provided by third-party consultants, partially offset by a decrease
in expenses related to legal and patent services.
For the six months ended June 30,
2024, Viking reported a net loss of $49.6 million, or $0.46 per share, compared to a net loss of
$38.8 million, or $0.44 per share, in the corresponding period in
2023. The increase in net loss for the six months ended
June 30, 2024, was primarily due to
the increase in research and development expenses and general and
administrative expenses, noted previously, partially offset by
increased interest income, compared to the same period in 2023.
Balance Sheet as of June 30,
2024
At June 30, 2024, Viking held
cash, cash equivalents and short-term investments of $942 million, compared to $362 million as of December 31, 2023.
Conference Call
Management will host a conference call to discuss Viking's
second quarter 2024 financial results today at 4:30 pm Eastern. To participate in the
conference call, please dial (844) 850-0543 from the U.S. or (412)
317-5199 from outside the U.S. In addition, following the
completion of the call, a telephone replay will be accessible until
July 31, 2024, by dialing (877)
344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and
entering conference ID # 4777459. Those interested in
listening to the conference call live via the internet may do so by
visiting the Webcasts page of Viking's website at
http://ir.vikingtherapeutics.com/webcasts. An archive of the
webcast will also be available on the Webcasts page of Viking's
website for 30 days.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development of novel first-in-class or
best-in-class therapies for the treatment of metabolic and
endocrine disorders, with three compounds currently in clinical
trials. Viking's research and development activities leverage
its expertise in metabolism to develop innovative therapeutics
designed to improve patients' lives. Viking's clinical
programs include VK2735, a novel dual agonist of the glucagon-like
peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide
(GIP) receptors for the potential treatment of various metabolic
disorders. Data from a Phase 1 and a Phase 2 trial evaluating
VK2735 (dosed subcutaneously) for metabolic disorders demonstrated
an encouraging safety and tolerability profile as well as positive
signs of clinical benefit. Concurrently, the company is evaluating
an oral formulation of VK2735 in a Phase 1 trial. Viking is also
developing VK2809, a novel, orally available, small molecule
selective thyroid hormone receptor beta agonist for the treatment
of lipid and metabolic disorders. The compound successfully
achieved both the primary and secondary endpoints in a recently
completed Phase 2b study for the treatment of
biopsy-confirmed non-alcoholic steatohepatitis (NASH) and
fibrosis. In a Phase 2a trial for the treatment of
non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C,
patients who received VK2809 demonstrated statistically significant
reductions in LDL-C and liver fat content compared with patients
who received placebo. The company's newest program is
evaluating a series of internally developed dual amylin and
calcitonin receptor agonists (or DACRAs) for the treatment of
obesity and other metabolic disorders. In the rare disease
space, Viking is developing VK0214, a novel, orally available,
small molecule selective thyroid hormone receptor beta agonist for
the potential treatment of X-linked adrenoleukodystrophy
(X-ALD). VK0214 is currently being evaluated in a
Phase 1b clinical trial in patients with the
adrenomyeloneuropathy (AMN) form of X-ALD.
For more information about Viking Therapeutics, please
visit www.vikingtherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements
regarding Viking Therapeutics, Inc., under the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995, including statements about Viking's expectations regarding
its clinical and preclinical development programs, anticipated
timing for reporting clinical data and cash resources.
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
and adversely and reported results should not be considered as an
indication of future performance. These risks and
uncertainties include, but are not limited to: risks associated
with the success, cost and timing of Viking's product candidate
development activities and clinical trials, including those for
VK2735, VK0214, VK2809, and the company's other incretin receptor
agonists; risks that prior clinical and preclinical results may not
be replicated; risks regarding regulatory requirements; and other
risks that are described in Viking's most recent periodic reports
filed with the Securities and Exchange Commission, including
Viking's Annual Report on Form 10-K for the year
ended December 31, 2023, and subsequent Quarterly Reports on
Form 10-Q, including the risk factors set forth in those filings.
These forward-looking statements speak only as of the date
hereof. Viking disclaims any obligation to update these
forward-looking statements except as required by law.
Viking Therapeutics,
Inc.
|
Consolidated
Statements of Operations and Comprehensive Loss
|
|
(In thousands,
except per share amounts)
|
(Unaudited)
|
|
|
|
Three Months
Ended
June 30,
|
|
|
Six Months Ended
June 30,
|
|
|
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2023
|
|
Revenues
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development
|
|
|
23,769
|
|
|
|
13,917
|
|
|
|
47,872
|
|
|
|
24,925
|
|
General and
administrative
|
|
|
10,285
|
|
|
|
9,823
|
|
|
|
20,255
|
|
|
|
19,352
|
|
Total operating
expenses
|
|
|
34,054
|
|
|
|
23,740
|
|
|
|
68,127
|
|
|
|
44,277
|
|
Loss from
operations
|
|
|
(34,054)
|
|
|
|
(23,740)
|
|
|
|
(68,127)
|
|
|
|
(44,277)
|
|
Other income
(expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of
financing costs
|
|
|
(18)
|
|
|
|
(32)
|
|
|
|
(46)
|
|
|
|
(60)
|
|
Interest income,
net
|
|
|
11,820
|
|
|
|
4,547
|
|
|
|
18,565
|
|
|
|
5,581
|
|
Realized gain on
investments, net
|
|
|
2
|
|
|
|
—
|
|
|
|
2
|
|
|
|
—
|
|
Total other income,
net
|
|
|
11,804
|
|
|
|
4,515
|
|
|
|
18,521
|
|
|
|
5,521
|
|
Net loss
|
|
|
(22,250)
|
|
|
|
(19,225)
|
|
|
|
(49,606)
|
|
|
|
(38,756)
|
|
Other comprehensive
loss, net of tax:
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized gain (loss)
on securities
|
|
|
(699)
|
|
|
|
(417)
|
|
|
|
(1,824)
|
|
|
|
84
|
|
Foreign currency
translation gain (loss)
|
|
|
26
|
|
|
|
(5)
|
|
|
|
(59)
|
|
|
|
(22)
|
|
Comprehensive
loss
|
|
$
|
(22,923)
|
|
|
$
|
(19,647)
|
|
|
$
|
(51,489)
|
|
|
$
|
(38,694)
|
|
Basic and diluted net
loss per share
|
|
$
|
(0.20)
|
|
|
$
|
(0.19)
|
|
|
$
|
(0.46)
|
|
|
$
|
(0.44)
|
|
Weighted-average shares
used to compute basic
and diluted net loss per share
|
|
|
110,390
|
|
|
|
99,010
|
|
|
|
106,924
|
|
|
|
88,738
|
|
Viking Therapeutics,
Inc.
|
Consolidated Balance
Sheets
|
|
(In thousands,
except share and per share amounts)
|
|
|
|
June 30,
2024
|
|
|
December 31,
2023
|
|
|
|
(Unaudited)
|
|
|
|
|
Assets
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
43,915
|
|
|
$
|
55,516
|
|
Short-term investments
– available-for-sale
|
|
|
898,348
|
|
|
|
306,563
|
|
Prepaid clinical trial
and preclinical study costs
|
|
|
3,323
|
|
|
|
2,624
|
|
Prepaid expenses and
other current assets
|
|
|
138
|
|
|
|
2,522
|
|
Total current
assets
|
|
|
945,724
|
|
|
|
367,225
|
|
Right-of-use
assets
|
|
|
977
|
|
|
|
1,126
|
|
Deferred financing
costs
|
|
|
105
|
|
|
|
106
|
|
Deposits
|
|
|
33
|
|
|
|
33
|
|
Total
assets
|
|
$
|
946,839
|
|
|
$
|
368,490
|
|
Liabilities and
stockholders' equity
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
11,090
|
|
|
$
|
7,512
|
|
Other accrued
liabilities
|
|
|
13,669
|
|
|
|
11,299
|
|
Lease liability,
current
|
|
|
334
|
|
|
|
324
|
|
Total current
liabilities
|
|
|
25,093
|
|
|
|
19,135
|
|
Lease liability, net
of current portion
|
|
|
766
|
|
|
|
936
|
|
Total long-term
liabilities
|
|
|
766
|
|
|
|
936
|
|
Total
liabilities
|
|
|
25,859
|
|
|
|
20,071
|
|
Commitments and
contingencies
|
|
|
|
|
|
|
Stockholders'
equity:
|
|
|
|
|
|
|
Preferred stock,
$0.00001 par value: 10,000,000 shares
authorized at June 30, 2024 and December 31, 2023; no
shares issued and outstanding at June 30, 2024 and
December 31, 2023
|
|
|
—
|
|
|
|
—
|
|
Common stock, $0.00001
par value: 300,000,000 shares
authorized at June 30, 2024 and December 31, 2023;
110,796,200 shares issued and outstanding at June 30,
2024 and 100,113,770 shares issued and outstanding at December 31,
2023
|
|
|
1
|
|
|
|
1
|
|
Treasury stock at
cost, no shares at June 30, 2024 and 2,193,251 shares at
December 31, 2023
|
|
|
—
|
|
|
|
(6,795)
|
|
Additional paid-in
capital
|
|
|
1,350,801
|
|
|
|
733,546
|
|
Accumulated
deficit
|
|
|
(427,550)
|
|
|
|
(377,944)
|
|
Accumulated other
comprehensive loss
|
|
|
(2,272)
|
|
|
|
(389)
|
|
Total stockholders'
equity
|
|
|
920,980
|
|
|
|
348,419
|
|
Total liabilities and
stockholders' equity
|
|
$
|
946,839
|
|
|
$
|
368,490
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-update-302205767.html
SOURCE Viking Therapeutics, Inc.